| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.19 | 0.0003 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.15 | 0.0004 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | 0.5 | 0.0005 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0005 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | 0.17 | 0.0007 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |